Repligen Total Liabilities 2010-2025 | RGEN

Repligen total liabilities for the quarter ending March 31, 2025 were $0.867B, a 2.41% decline year-over-year.

  • Repligen total liabilities for 2024 were $0.857B, a 1.08% decline from 2023.
  • Repligen total liabilities for 2023 were $0.866B, a 39.53% increase from 2022.
  • Repligen total liabilities for 2022 were $0.621B, a 2.07% increase from 2021.

Repligen Total Liabilities 2010-2025 | RGEN

  • Repligen total liabilities for 2024 were $0.857B, a 1.08% decline from 2023.
  • Repligen total liabilities for 2023 were $0.866B, a 39.53% increase from 2022.
  • Repligen total liabilities for 2022 were $0.621B, a 2.07% increase from 2021.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$213.3B
Amgen (AMGN)$158.5B
Gilead Sciences (GILD)$134.6B
Vertex Pharmaceuticals (VRTX)$118.1B
Bristol Myers Squibb (BMY)$96.4B
CSL (CSLLY)$81.2B
GSK (GSK)$74.3B
Regeneron Pharmaceuticals (REGN)$58.6B
Alnylam Pharmaceuticals (ALNY)$41.8B
Argenex SE (ARGX)$34.6B
BioNTech SE (BNTX)$26.4B
Royalty Pharma (RPRX)$20B
Insmed (INSM)$19.5B
Biogen (BIIB)$18.3B
Illumina (ILMN)$15.2B
Genmab (GNMSF)$14.3B
Genmab (GMAB)$14B
Incyte (INCY)$13.1B
Exelixis (EXEL)$12.1B
Moderna (MRNA)$12.1B
BioMarin Pharmaceutical (BMRN)$11B
QIAGEN (QGEN)$10.7B
Swedish Orphan Biovitrum (BIOVF)$10.6B
Ascendis Pharma (ASND)$10.4B
Exact Sciences (EXAS)$9.5B
Verona Pharma American Depositary Share (VRNA)$8.9B
Blueprint Medicines (BPMC)$8.3B
Bio-Techne Corp (TECH)$8.2B
Roivant Sciences (ROIV)$7.8B
Legend Biotech (LEGN)$7.6B